Global Narcolepsy Therapeutics Market to Reach US$395 Million by 2015, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a global report on Narcolepsy Therapeutics market. The global market for Narcolepsy Therapeutics is projected to exceed US$395 million by the year 2015. Though a relatively small market, the global narcolepsy market exhibited significant growth since 2003, driven by an increase in awareness about the disorder and substantial market penetration of two key drugs used in the treatment of narcolepsy - Provigil (Modafinil) and Xyrem (Sodium oxybate). Patent expiry of Provigil in 2012 and black box warning for Xyrem provide significant room for other novel therapeutics, especially those with enhanced safety and efficacy.

Narcolepsy Therapeutics: A Global Market Report

Sleep disorders affect millions of people worldwide. The overall prevalence of sleep disorders is very high, with about 70 million people suffering from some kind of this disorder in the US alone. A high level of significant unmet needs exist in the sleep disorders market, presenting substantial opportunities for pharma players. Narcolepsy, also known as dyssomnia, is a chronic neurological sleep disorder, caused due to the brain's inability to regulate normal sleep-wake cycles. The disorder affects around 3 million people worldwide, and around 200,000 in the US. Two major symptoms of narcolepsy include Cataplexy and excessive daytime sleepiness.

The global market for Narcolepsy Therapeutics is dominated by two key FDA approved drugs, Provigil and Xyrem, as stated by the new market research report on Narcolepsy Therapeutics. Provigil continues to be the most widely prescribed option in the treatment of narcolepsy. Although a market leader, Provigil faces challenges of patent expiry in 2012; and competition from Xyrem. Nuvigil (Armodafinil) from Cephalon is the single isomer formulation of Provigil, developed with an aim to retain the company’s leadership in narcolepsy therapeutics market, following the patent expiry of its leading narcolepsy drug Provigil.

Key players profiled in the report include Addrenex Pharmaceuticals, Arena Pharmaceuticals Inc., Cephalon Inc., Evotec AG, Hypnion Inc., and Jazz Pharmaceuticals Inc.

The report titled “Narcolepsy Therapeutics: A Global Market Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the global narcolepsy market, the leading marketed drugs for narcolepsy, patent expiries, market trends, growth drivers, drug approvals and other regulatory filings, patent infringement lawsuits, recent corporate initiatives, and focus on select market participants. The study analyzes market data and analytics in terms of value sales for the global market.

For more details about this market research report, please visit –

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press(at)StrategyR(dot)com
Web Site

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website